The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M03 | Muscle relaxants | |
| 3 | M03C | Muscle relaxants, directly acting agents | |
| 4 | M03CA | Dantrolene and derivatives | |
| 5 | M03CA01 | Dantrolene |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.1 g |
| Active Ingredient | Description | |
|---|---|---|
| Dantrolene |
The receptor molecule for dantrolene has not been identified. Dantrolene inhibits the binding of ryanodine. Under some conditions, dantrolene will lower intra-sarcoplasmic calcium concentrations in the resting state. This may be more important in diseased muscle (e.g. In malignant hyperthermia in humans and swine stress syndrome) than in muscle with normal function. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DANTRIUM Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| DANTRIUM Powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
